Final Results

Tekcapital plc

("Tekcapital", "the Company" or "the Group")

Preliminary Results for the year-ended 30 November 2015

Tekcapital plc (AIM:TEK), an international provider of technology and intellectual property services, announces its preliminary results for the year-ended 30 November 2015.

Operational Highlights

· Acquired the exclusive license rights to 50 patents to date.

· Continued to expand the InventionEvaluator® service with the addition of a direct sales team in the US and the recent upgrade to enhance both the content and marketability of the reports.

Post-period end highlights

· Acquisition of the business of the Vortechs Group, a leading technology transfer placement firm in North America.

· Acquisition of the exclusive licenses to manufacture and sell three proprietary medical devices from Stryker Corporation into Belluscura Ltd, a newly formed company set up by Tekcapital to commercialise these products.

Commenting on the results, Dr. Clifford Gross, Executive Chairman of Tekcapital plc said:

"We are pleased to announce we have continued to develop the business during 2015, which now holds license rights to a total of 50 patents. We remain confident that meaningful near-term revenues will arise from commercialising our IP portfolio."

"As the market opportunity for the Company continues to expand and large enterprises increasingly take advantage of exogenous innovations, the Company will continue to invest in its IP portfolio while evaluating further commercial opportunities for its existing licenses."

Copies of the Company's Annual Report and Accounts will be posted to shareholders next week, together with a notice of the Annual General Meeting to be held at 2.00 p.m. on 27 May 2016 at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London EC4M 7RD.

For further information, please contact:

Tekcapital plc - The World's Largest University Network for Open Innovation

Tekcapital helps clients profit from new, university-developed intellectual properties. With our proprietary discovery search engine, linked to 4,000+ universities in 160 countries, coupled with expert scientific review, we provide a turn-key service to make it easy for clients to find and acquire the IP, analytics and technology transfer professionals they need to create a competitive advantage. Tekcapital plc is listed on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com 

Chairman's statement

Review of the Business

The Tekcapital group is engaged in helping its clients to profit from university intellectual property (IP). Since last year we have made considerable progress.

We continue to provide technology sourcing services for our corporate clients but also provide three important additional services:

· Acquiring the exclusive license to potentially disruptive technologies for our own portfolio for subsequent development and commercialisation. Since we began this service in January 2015, to-date we have acquired the exclusive rights to 50 patents.

· In 2014 we announced the acquisition of InventionEvaluator, the turn-key service that assesses the commercial potential of new technologies. We continue to expand the client base for the service and have added a direct sales team in our US office. Additionally, we have recently up-graded the format of the reports to enhance both their information content and marketability.

· Post end of period we were very pleased to have announced the acquisition of the business and certain assets of the Vortechs Group, a leading technology transfer placement firm in North America. For operating the Vortechs Group's business on behalf of Tekcapital and for covering all related business expenditures going forward, Tekcapital will pay Vortechs Group a management and service fee, based on revenue achieved, for a minimum period of five years. This expands our business offerings and enables us to provide technology transfer professionals as well as new technologies to both our clients and university suppliers.

Additionally, post end of period we are pleased to have also announced the acquisition of the exclusive licences to manufacture and sell three proprietary medical devices from Stryker Corporation into Belluscura Ltd, a newly formed company set up by Tekcapital to commercialise these products. Belluscura Ltd's mission is to address the marketplace need for premium medical devices at affordable prices. The devices have been developed by and exclusively licensed from Stryker Corporation, a leading medical technology company. The devices have achieved regulatory clearances where necessary and have already achieved commercial sales under Stryker.

The medical devices are:

· "SlydeTM", a non-ambulatory patient evacuation sled.

· "Passport", a trocar for use with the Da Vinci® Surgical System (keyhole surgery).

· "SNAP II", a level of consciousness monitor for use during surgical procedures requiring general anaesthesia.

The products are protected by a portfolio of 19 issued and pending patents and industrial designs. Belluscura has been established in order to commercialise these products, for which a new management team is being put in place. It is intended that Belluscura will market and expand the sales of the devices, initially in the US and Western Europe, using third party manufacturing and will look to acquire additional medical devices to sell in the future. Tekcapital is exploring the possibility of Belluscura raising funds via an IPO on AIM to accelerate its growth strategy. Tekcapital owns 95% of the share capital of Belluscura and Stryker Corporation owns the remaining 5%. 

Divisional Review

Demand for the Group's Invention Evaluator service remains strong with customers consisting of universities, research centres and corporations world-wide. The service has been successfully integrated with our existing offering and has attracted significant interest.

The Group's technology out-licensing service leverages its competencies to identify and acquire particularly promising new IP which management believes can be readily out-licensed to corporations. This service extends the Group's impact by directly commercialising innovative university and corporate developed technologies and also has the potential to capture for the Group's own benefit more of the value realised when innovative ideas are successfully commercialised. Since inception a year ago, this new effort has grown rapidly. As of the date of this report we have secured exclusive licenses to 50 patents, applications and industrial designs. We have a number of on-going commercialisation opportunities that we hope to progress in the near future. We are making solid progress on our commercialisation programmes for a number of our licensed properties and believe that we will be in a position to update the market in due course. The Directors believe that the post period announcements of the acquisition of the Vortechs Group business and the establishment of Belluscura Ltd should make a significant contribution to our Group's financial performance in future reporting periods.

Current Trading and Outlook

Having continued to develop its existing business, the Board is confident that continued investment in growth is the right policy. We believe this strategy is likely to lead to increased revenue in 2016 as we continue to seize additional opportunities with the potential for adding considerable shareholder value.

The Directors remain confident that meaningful revenues will arise from our service offerings combined with the near-term sub-licensing or external funding of licenses held in its IP portfolio. With an increasing number of companies making ever faster and more disruptive use of innovative ideas sourced exogenously, and with patented university and corporate technologies an increasingly valued currency, the market opportunity for the Group is both large and continuing to grow.

Financial review

The Group is still in its early stages of development. Funds raised from investors are being applied, along with revenues generated, to pursuing our strategic objectives. These are principally to grow the customer base for our technology transfer services and to acquire and sell on licences for certain university and corporate intellectual properties.

Group sales for the period to 30 November 2015 were US $407,420 (as compared with sales of US $210,337 in 2014) with losses of US $1,460,815 as compared with losses of US $994,869 in 2014.

The Group's assets grew from US $1,818,352 to US $3,961,698 during the period mainly thanks to shareholder investment during the year, augmented by technology acquisitions. The Group's liabilities are very low at the end of the period because its costs have been settled without delay, using funds from the cash reserves invested since our IPO and subsequent capital raise in May of 2015.

Clifford M Gross

Chairman and CEO

28 April 2016 

Consolidated Statement of comprehensive income

For the year ended 30 November 2015

Loss per share

The Group has used the exemption under S408 CA 2006 not to disclose the company income statement. Items in the statement above are disclosed net of tax.

Consolidated Statement of financial position

At 30 November 2015

Statement of financial position

At 30 November 2015

Statements of changes in equity

For the year ended 30 November 2015

Consolidated Statement of cash flows

For the year ended 30 November 2015

Selected Notes to the accounts

For the year ended 30 November 2015

1. General Information

Tekcapital PLC is a company incorporated in England and Wales and domiciled in the UK. The address of the registered office is detailed on page 1 of these financial statements. The Company is a public limited company, which is listed on the AIM market of the London Stock Exchange.

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

2.1 Statement of compliance

The financial statements of Tekcapital PLC have been prepared in accordance with International Financial Reporting Standards (IFRS) and IFRS Interpretations Committee (IFRS IC) as adopted by the European Union and the Companies Act 2006 applicable to companies reporting under IFRS. The financial statements have been prepared under the historical cost convention.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It requires management to exercise its judgement in the process of applying the group's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in note 4.

2.1.1 Going concern

The Group meets its day to day working capital requirements through its bank facilities and monies raised by an initial public offering made April 2014 and an equity fundraise in May 2015. The Group's forecasts and projections indicate that the Group has sufficient cash reserves to operate within the level of its current facilities. After making enquiries, the Directors have a reasonable expectation that the Group had adequate resources to continue in operational existence for the foreseeable future.

The Group delivered an operating loss of US$1,460,704 before tax. Cash inflow from financing activities was strong due to the equity fund raise in May 2015.

The Company therefore continues to adopt the going concern basis in preparing both its consolidated financial statements and for its own financial statements. 

3. Segmental reporting

The Directors consider the business to have two segments for reporting purposes under IFRS 8 which are:

· professional services, including the provision of reports and any services provided to locate and transfer technologies to customers

· licensing activities, including acquiring licenses for technologies and their subsequent out licensing

Segmental revenues and results

Segment assets and liabilities

Geographical information

Disclosure of Group revenues by geographic location.

4. Income tax expense

The tax on the Group's loss before tax differs from the theoretical amount that would arise using the weighted average tax rate applicable to losses.

The weighted average applicable tax rate was 20%. The increase is caused by a standard amount of tax payable in those States in the USA which a subsidiary company operates from and is not attributable to the level of profits or losses incurred.

Unused tax losses for which no deferred tax assets have been recognised is attributable to the uncertainty over the recoverability of those losses through future profits.

5. Loss per share

Any options and warrants do not have a dilutive effect on the EPS as the Group is loss-making.

6. Investments in subsidiaries

* 100% subsidiary of Tekcapital Europe Limited

The Group owns 100% of the above subsidiaries and consequently has full control over them. As at the year end, the Group has no interest in the ownership of any other entities, or exerts any significant influence over or provides funding which constitutes an "unconsolidated structured entity".

All UK subsidiaries are exempt from the requirement to file audited accounts by virtue of section 479A of the Companies Act 2006. As part of this process, the Company has provided statutory guarantees to these subsidiaries.

The Company's loss before tax for the year ended 30 November 2015 was $632,183.

7. Intangible assets

Under IAS38, the Group's Invention Evaluator is regarded by the Directors as being an intangible asset with an indefinite useful life. The Directors believe that the asset is unique in that no competitor offering currently exists, the service is already proven to have appeal globally to many types of clients including Fortune 100 companies, there is no expectation of obsolescence in the foreseeable future, and the service generates sufficient on-going revenue streams. The Directors have carried out an impairment review and believe that the value in use is significantly greater than book value.

8. Dividends

No dividend has been declared for the year ended 30 November 2015 (2014: Nil) and no dividend was paid during the year.

9. Cash generated from operations

10. Events after the reporting period

At the time of signing these accounts, the Directors had completed the acquisition of the business of the Vortechs Groups Inc. ("Vortechs Group"). Consideration for the acquisition was by way of $100,000 cash and the issue of 577,868 new ordinary share of 0.4 pence to Vortechs Group at an issue price of £0.475 per share.

The acquisition has been structured so that Tekcapital acquires the intellectual capital assets of Vortechs Group and certain other assets of the business. Tekcapital will not acquire the Vortechs Group corporate entity and certain of its fixed assets. Additionally, Tekcapital will not acquire or assume any of Vortechs Group's liabilities.